Banner Title
의료진 소개
조현지 교수
혈액종양내과, 암센터, 유방암센터 관심의료진 등록전문 진료 분야
폐암, 유방암, 대장ㆍ직장암 , 부인종양 , 육종암, 흑색종, 기타고형암
진료 일정
학력사항
- 이화여자대학교 의학전문대학원 졸업
- 이화여자대학교 의학박사
교육 및 연구경력
- 현재 | 이대서울병원 혈액종양내과 조교수
- 이대서울병원 혈액종양내과 임상조교수
- 삼성서울병원 혈액종양내과 임상강사
- 이대목동병원 혈액종양내과 전임의
- 이대목동병원 내과 전공의
- 이대목동병원 인턴
수상경력
- 2022 | Global Breast Cancer Conference Young Investigator Award
기타 학술 관련 경력
- 대한종양내과학회 정회원
- 대한항암요법연구회 정회원
- 대한내과학회 정회원
논문
- Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer. Therapeutic Advances in Gastroenterology. 2022-08.
- A Phase II Study of Preoperative Chemoradiotherapy with Capecitabine Plus Simvastatin in Patients with Locally Advanced Rectal Cancer. Cancer Research and Treatment. 2022-06.
- Impact of COPD Treatment on Survival in Patients with Advanced Non-Small Cell Lung Cancer. Journal of Clinical Medicine. 2022-04.
- A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma. Frontiers in Oncology. 2022-04.
- Role of upfront autologous stem cell transplantation in patients newly diagnosed with primary CNS lymphoma treated with R-MVP: real-world data from a retrospective single-center analysis. Bone Marrow Transplantation. 2022-04.
- A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer. Clinical Oncology. 2022-03.
- Comprehensive comparison of international prognostic indexes for follicular helper T-cell lymphoma. Annals of Hematology. 2022-03.
- Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI. Cancer Research and Treatment. 2022-03.
- HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer. Frontiers in Oncology. 2022-02.
- Long-Term Breast Cancer Outcomes of Pregnancy-Associated Breast Cancer (PABC) in a Prospective Cohort. Cancers. 2022-01.
- Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer. Technology in Cancer Research & Treatment. 2021-12.
- The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers. Frontiers in Oncology. 2021-12.
- Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach. Cancers. 2021-11.